As mentioned, IL-1 is also emerging as a cytokine involved in drug resistance; we recently reported that increased levels of tumor-derived IL-1 are correlated with cetuximab resistance in colorectal cancer xenopatients and that abundance of IL-1R1 is predictive of therapy response [72]. This evidence concerns the gene IL1R1 and colorectal cancer.